<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uz">
	<id>https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=BioNTech</id>
	<title>BioNTech - Oʻzgarishlar tarixi</title>
	<link rel="self" type="application/atom+xml" href="https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=BioNTech"/>
	<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=BioNTech&amp;action=history"/>
	<updated>2026-11-20T01:54:54Z</updated>
	<subtitle>Ziyosferadagi mazkur sahifaning oʻzgarishlar tarixi</subtitle>
	<generator>MediaWiki 1.45.1</generator>
	<entry>
		<id>https://ziyosfera.uz/index.php?title=BioNTech&amp;diff=329320&amp;oldid=prev</id>
		<title>Programmer: Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.</title>
		<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=BioNTech&amp;diff=329320&amp;oldid=prev"/>
		<updated>2026-08-10T15:17:31Z</updated>

		<summary type="html">&lt;p&gt;Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Yangi sahifa&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;Biontech SE&amp;#039;&amp;#039;&amp;#039; ([[inglizcha]]: &amp;#039;&amp;#039;[Eire: ˈnektek]&amp;#039;&amp;#039;) — [[nemis]] biotexnologiya kompaniyasi, ishlab chiqish va jiddiy kasalliklarni davolash uchun individual yondashuv uchun faoli mmunoterapiyalarni ishlab chiqarish bilan shugʻullanadi. Kompaniya messenjer RNK (mRNK) asosidagi dori-darmonlarni individuallashtirilgan saraton immunoterapiyasi, yuqumli kasalliklarga qarshi vaktsinalar va kamdan-kam uchraydigan kasalliklar uchun oqsilni almashtirish terapiyasi sifatida, shuningdek ishlab chiqilgan hujayra terapiyasi, yangi antikorlar va kichik molekulalar, immunomodulyatorlar va boshqalarni oʻrganmoqda&amp;lt;ref name=&amp;quot;:0&amp;quot;&amp;gt;{{veb manbasi|lang=en|url=https://sec.report/Document/0001193125-19-241112/|title=Form F-1 Biontech Se — Registration statement for certain foreign private issuers|publisher=[[Комиссия по ценным бумагам и биржам]]|access-date=2020-09-30|archive-date=2021-02-14|archive-url=https://web.archive.org/web/20210214094009/https://sec.report/Document/0001193125-19-241112/|deadlink=no}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Tarix ==&lt;br /&gt;
BioNTech kompaniyasi 2008-yilda Ugur Shahin, Christoph Huber va Ozlem Turkeji tadqiqotlari asosida tashkil etilgan. Shundan beri kompaniya Rolf Zinkernagel boshchiligidagi ilmiy maslahat kengashi tomonidan qoʻllab-quvvatlandi&amp;lt;ref name=&amp;quot;:0&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2019-yil sentabr oyida BioNTech Bill va Melinda Geyts jamgʻarmasi bilan OIV infektsiyasi, sil va boshqa kasalliklarning oldini olish uchun dori vositalariga asoslangan klinikagacha vaktsinalar va immunoterapiya nomzodlarini yaratish va rivojlantirish dasturlarini ishlab chiqish boʻyicha shartnoma imzoladi&amp;lt;ref&amp;gt;{{veb manbasi|url=https://www.thepharmaletter.com/article/the-gates-foundation-sees-biontech-potential-to-dramatically-reduce-global-hiv-and-tuberculosis|title=The Gates Foundation sees BioNTech potential to ʻdramatically reduce global HIV and tuberculosis’|website=www.thepharmaletter.com|accessdate=2020-09-30|archive-date=2020-11-14|archive-url=https://web.archive.org/web/20201114132824/https://www.thepharmaletter.com/article/the-gates-foundation-sees-biontech-potential-to-dramatically-reduce-global-hiv-and-tuberculosis|deadlink=no}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2019-yil oktabr oyida kompaniya aksiyalari [[Nasdaq]] listingiga qoʻyildi.&lt;br /&gt;
&lt;br /&gt;
2019-yil dekabr oyida Yevropa investitsiya banki va BioNTech kompaniya Yevropa uchun investitsiya rejasi&amp;lt;ref&amp;gt;{{veb manbasi|lang=en|url=https://ec.europa.eu/commission/presscorner/home/en|title=Press corner|website=European Commission — European Commission|accessdate=2020-09-30|archive-date=2020-08-25|archive-url=https://web.archive.org/web/20200825095835/https://ec.europa.eu/commission/presscorner/home/en|deadlink=no}}&amp;lt;/ref&amp;gt; dasturi doirasida 50 million yevro miqdorida mablagʻ olishini eʼlon qildi.&lt;br /&gt;
&lt;br /&gt;
2020-yilning iyun oyida BioNTech Singapur Temasek Holdings va boshqa investorlar tomonidan almashtiriladigan obligatsiyalarni xususiy joylashtirishning bir qismi sifatida 250 million yevro oldi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi|accessdate=2020-09-30|first=Ludwig|last=Burger|date=2020-06-29|website=Reuters|title=Temasek-led investor group in $250 million vaccine bet on Germany&amp;#039;s BioNTech|url=https://www.reuters.com/article/us-biontech-placement-idUSKBN2400PS|archivedate=2020-10-17|archiveurl=https://web.archive.org/web/20201017220311/https://www.reuters.com/article/us-biontech-placement-idUSKBN2400PS}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2021-oktabr oyida kompaniya Afrika Ittifoqi hududida birinchi mRNA (Ruandada) vaktsina ishlab chiqaradigan zamonaviy zavodni joylashtirishni rejalashtirganini eʼlon qildi. Qurilish 2022-yil oʻrtasida boshlanadi. Rejalarga koʻra, birinchi ishga tushirilgan ishlab chiqarish liniyasi yiliga taxminan 50 million dozada dori-darmon ishlab chiqarishi mumkin. Kelgusida ishlab chiqarish quvvati qitʼadagi ishlab chiqarish tarmogʻiga qoʻshimcha liniyalar va uchastkalarni qoʻshish orqali bosqichma-bosqich oshiriladi, bu esa mRNK asosidagi vaksinaning bir necha yuz million dozasini ishlab chiqarish darajasiga erishish imkonini beradi&amp;lt;ref&amp;gt;{{veb manbasi|url=https://tass.ru/ekonomika/12769621|title=BioNTech начнет строительство завода по производству мРНК-вакцин в Африке в 2022 году|website=ТАСС|access-date=2021-10-26|archive-date=2021-10-26|archive-url=https://web.archive.org/web/20211026185805/https://tass.ru/ekonomika/12769621|deadlink=no}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== COVID-19 vaktsinasini ishlab chiqish ==&lt;br /&gt;
2020-yildan beri kompaniya Pfizer&amp;lt;ref name=&amp;quot;cnbc.com&amp;quot;&amp;gt;{{veb manbasi|lang=en|url=https://www.cnbc.com/2020/07/27/pfizer-and-biontech-began-late-stage-human-trial-for-coronavirus-vaccine-monday.html|title=Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday|author=Berkeley Lovelace Jr|website=CNBC|date=2020-07-27|accessdate=2020-09-30|archive-date=2020-11-14|archive-url=https://web.archive.org/web/20201114132900/https://www.cnbc.com/2020/07/27/pfizer-and-biontech-began-late-stage-human-trial-for-coronavirus-vaccine-monday.html|deadlink=no}}&amp;lt;/ref&amp;gt; va Fosun Pharmaceutical&amp;lt;ref name=&amp;quot;cnbc.com&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;{{yangiliklar manbasi|accessdate=2020-09-30|date=2020-04-23|website=Reuters|title=Germany approves trials of COVID-19 vaccine candidate|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-biontech-idUSKCN2241DN|archivedate=2020-11-28|archiveurl=https://web.archive.org/web/20201128000157/https://www.reuters.com/article/us-health-coronavirus-vaccine-biontech-idUSKCN2241DN}}&amp;lt;/ref&amp;gt; bilan birgalikda COVID-19ga qarshi emlashda ish boshladi.&lt;br /&gt;
&lt;br /&gt;
Pfizer va BioNTech buyuk Britaniya&amp;lt;ref&amp;gt;{{yangiliklar manbasi|accessdate=2020-09-30|first=James|last=Gallagher|date=2020-07-20|website=BBC News|title=UK signs deals for 90 million virus vaccine doses|url=https://www.bbc.com/news/health-53469269|archivedate=2020-11-14|archiveurl=https://web.archive.org/web/20201114133013/https://www.bbc.com/news/health-53469269}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{yangiliklar manbasi|accessdate=2020-09-30|first=Alistair|last=Smout|date=2020-07-21|website=Reuters|title=Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva|url=https://www.reuters.com/article/us-health-coronavirus-britain-vaccines-idUSKCN24L0GN|archivedate=2020-09-29|archiveurl=https://web.archive.org/web/20200929092142/https://www.reuters.com/article/us-health-coronavirus-britain-vaccines-idUSKCN24L0GN}}&amp;lt;/ref&amp;gt; uchun 30 million dozada vaktsina, AQSh&amp;lt;ref&amp;gt;{{yangiliklar manbasi|accessdate=2020-09-30|first=Michael Erman, Ankur|last=Banerjee|date=2020-07-22|website=Reuters|title=U.S. to pay Pfizer, BioNTech 12.95 billion for COVID-19 vaccine|url=https://www.reuters.com/article/us-health-coronavirus-usa-pfizer-idUSKCN24N1I9|archivedate=2020-07-22|archiveurl=https://web.archive.org/web/20200722171010/https://www.reuters.com/article/us-health-coronavirus-usa-pfizer-idUSKCN24N1I9}}&amp;lt;/ref&amp;gt; uchun 100 million doz va Yaponiya uchun 120 million dozani etkazib berish boʻyicha shartnoma imzoladilar.&lt;br /&gt;
&lt;br /&gt;
2020-yil 9-noyabrda , BioNTech va Pfizer, COVID-19 vaktsinasining test maʼlumotlarini dastlabki tahlil qilish 90 % dan koʻproq samarali ekanligini koʻrsatdi&amp;lt;ref&amp;gt;{{veb manbasi|lang=ru|url=https://mosmedpreparaty.ru/news/21646|title=Коронавирус. Вакцины. Pfizer и BioNTech: первая реальная победа над ковидом!|author=Дмитриев, Р.|coauthors=Фон Ройсс, Т., Стрельцова, Ю., Губарев, А.|website=Mosmedpreparaty.ru|subtitle=мРНК-вакцина обеспечила высочайшую эффективность защиты от ковида и готова остановить пандемию коронавируса|date=2020-11-09|publisher=Мосмедпрепараты|accessdate=2020-11-12|archive-date=2020-11-12|archive-url=https://web.archive.org/web/20201112231606/https://mosmedpreparaty.ru/news/21646|deadlink=no}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{veb manbasi |url=https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-geben-erfolgreiche-erste-zwischenanalyse |title=Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt |publisher=BioNTech |date=2020-11-09 |accessdate=2020-11-09 |archiveurl=https://web.archive.org/web/20201109114825/https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-geben-erfolgreiche-erste-zwischenanalyse |archivedate=2020-11-09 |lang=de |deadlink=no }}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{veb manbasi |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against |title=Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study |publisher=[[Pfizer]] |date=2020-11-09 |accessdate=2020-11-09 |archiveurl=https://web.archive.org/web/20201109115347/https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against |archivedate=2020-11-09 |lang=en |deadlink=no }}&amp;lt;/ref&amp;gt;. Klinik tadqiqotlarning davom etayotgan uchinchi bosqichi deb ataladigan oraliq tahlil doirasida COVID-19 kasalligining birinchi 94 ta tasdiqlangan holatlari 43 000 koʻngillilari orasida ikkita vaktsina yoki platsebo olgan. Vaksinani kiritgan ishtirokchilar orasida keyinchalik 10% dan kam boʻlgan va platsebo berilgan ishtirokchilar orasida yuqtirilganlarning 90% dan koʻprogʻi borligi aniqlandi. Ushbu natija kompaniyalarga AQSh oziq-ovqat va farmatsevtika idorasiga (FDA) vaktsinani shu oyning boshida foydalanish uchun tasdiqlash uchun murojaat qilish imkonini beradi. Favqulodda holatlarda foydalanish uchun vaktsinani tasdiqlash, FDA maʼlumotlariga koʻra, samaradorligi kamida 50 % boʻlgan taqdirda mumkin. BioNTech va Pfizer farmatsevtika kompaniyalari vaktsina samaradorligini aniqroq aniqlash uchun sinovdan oʻtganlar orasida tasdiqlangan COVID-19 holatlari soni 164ga&amp;lt;ref&amp;gt;{{veb manbasi |url=https://edition.cnn.com/2020/11/09/health/pfizer-covid-19-vaccine-effective/index.html |title=Pfizer says early analysis shows its Covid-19 vaccine is more than 90% effective |author=Kounang, Nadia |publisher=[[CNN]] |date=2020-11-09 |accessdate=2020-11-09 |archiveurl=https://web.archive.org/web/20201109114655/https://edition.cnn.com/2020/11/09/health/pfizer-covid-19-vaccine-effective/index.html |archivedate=2020-11-09 |lang=en |deadlink=no }}&amp;lt;/ref&amp;gt; yetguncha vaksinaning klinik sinovlarini davom ettirmoqchi.&lt;br /&gt;
&lt;br /&gt;
2020-yil 11-dekabrda FDA AQShda COVID-19 vaktsinasidan foydalanishni tasdiqladi&amp;lt;ref&amp;gt;{{Статья|url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine|title=Pfizer-BioNTech COVID-19 Vaccine|archive-date=2020-12-12|archive-url=https://web.archive.org/web/20201212030749/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2022-yil mart oyi boshida Pfizer va BioNTech 3,1 milliard doza vaksina yetkazib berdi.&lt;br /&gt;
&lt;br /&gt;
== Egalari va boshqaruvi ==&lt;br /&gt;
Eng yirik aktsiyador (43,8 %) aka-uka Andreas va Tomas Strüngmannlarga (Andreas und Thomas Strungmann) tegishli boʻlgan AT Impf GmbH boʻlib, 2008-yilda ular kompaniyaga 150 million yevro sarmoya kiritgan&amp;lt;ref&amp;gt;{{Статья|ссылка=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine|автор=Office of the Commissioner|заглавие=Pfizer-BioNTech COVID-19 Vaccine|год=2020-12-14|язык=en|издание=FDA|archivedate=2020-12-12|archiveurl=https://web.archive.org/web/20201212030749/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{veb manbasi |title=COVID-19 vaccine hopes have made these twins $8 billion richer |url=https://nypost.com/2020/11/13/covid-19-vaccine-hopes-have-made-these-twins-8-billion-richer/ |publisher=NYP Holdings, Inc. |date=2020-11-13 |accessdate=2022-04-09 |lang=en |archive-date=2022-04-09 |archive-url=https://web.archive.org/web/20220409135326/https://nypost.com/2020/11/13/covid-19-vaccine-hopes-have-made-these-twins-8-billion-richer/ |deadlink=no }}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
Hammuassisi va boshqaruvchi Uguru Shahin kompaniyasi Medine GmbH orqali aktsiyalar 17,1 % egalik qiladi.&lt;br /&gt;
&lt;br /&gt;
== Faoliyat ==&lt;br /&gt;
Kompaniyaning Marburgdagi zavodi (2020-yil oktabr oyida Novartisdan sotib olingan), vaksinalarning asosiy qismi Pfizer va uchinchi tomon pudratchi kompaniyalari, xususan, Janubiy Afrikadagi Biovac instituti va Braziliyadagi Eurofarma Laboratorios korxonalarida ishlab chiqariladi.&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
|+Moliyaviy koʻrsatkichlar milliard evro&lt;br /&gt;
!&lt;br /&gt;
! 2017-yil&lt;br /&gt;
! 2018-yil&lt;br /&gt;
! 2019&lt;br /&gt;
! 2020&lt;br /&gt;
! 2021-yil&lt;br /&gt;
|-&lt;br /&gt;
| Aylanma&lt;br /&gt;
| 0,062&lt;br /&gt;
| 0,128&lt;br /&gt;
| 0,109&lt;br /&gt;
| 0,482&lt;br /&gt;
| 18.977&lt;br /&gt;
|-&lt;br /&gt;
| Sof foyda&lt;br /&gt;
| −0,086&lt;br /&gt;
| −0,048&lt;br /&gt;
| −0,179&lt;br /&gt;
| 0,015&lt;br /&gt;
| 10.293&lt;br /&gt;
|-&lt;br /&gt;
| Aktivlar&lt;br /&gt;
| 0,375&lt;br /&gt;
| 0,653&lt;br /&gt;
| 0,798&lt;br /&gt;
| 2.319&lt;br /&gt;
| 15.831&lt;br /&gt;
|-&lt;br /&gt;
| Kapital&lt;br /&gt;
| −0,049&lt;br /&gt;
| 0,266&lt;br /&gt;
| 0,493&lt;br /&gt;
| 1.372&lt;br /&gt;
| 11 894&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== Yana qarang ==&lt;br /&gt;
&lt;br /&gt;
* Dunyodagi eng yirik farmatsevtika kompaniyalari roʻyxati&lt;br /&gt;
* [[Moderna|Zamonaviy]]&lt;br /&gt;
&lt;br /&gt;
== Manbalar ==&lt;br /&gt;
{{manbalar}}&lt;br /&gt;
&amp;lt;references responsive=&amp;quot;1&amp;quot;&amp;gt;&amp;lt;/references&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Havolalar ==&lt;br /&gt;
&lt;br /&gt;
* [https://biontech.de/ Официальный сайт компании]&lt;br /&gt;
&lt;br /&gt;
[[Turkum:Germaniyadagi farmatsevtika kompaniyalari]]&lt;br /&gt;
[[Turkum:Internetdan iqtibos keltiring (til ko&amp;#039;rsatilmagan)]]&lt;br /&gt;
[[Turkum:Vikipediyadan olingan manbalar bilan maqolalar]]&lt;br /&gt;
[[Turkum:Rus tilisiz Vikidata ob&amp;#039;ektlariga havolali maqolalar]]&lt;br /&gt;
[[Turkum:NASDAQ ro&amp;#039;yxatiga kiritilgan kompaniyalar]]&lt;/div&gt;</summary>
		<author><name>Programmer</name></author>
	</entry>
</feed>